The combination of the anti-EGFR antibody cetuximab and RT received clinical approval for the treatment of HNSCC in 2008, but in fact, this has since remained the only approved molecular targeting approach in combination with RT. Here, EGFR is linked to head and neck squamous cell carcinoma.